August 6, 2004 Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting. Salahpour A, Angers S, Mercier JF, Lagacé M, Marullo S, Bouvier MJ. Biol. Chem. 2004-08-06 ;279( 32 ):33390-7
August 1, 2004 Analysis of protein phosphorylation by hypothesis-driven multiple-stage mass spectrometry. Chang EJ, Archambault V, McLachlin DT, Krutchinsky AN, Chait BTAnal. Chem. 2004-08-01 ;76( 15 ):4472-83
August 1, 2004 Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059. Bernier V, Lagacé M, Lonergan M, Arthus MF, Bichet DG, Bouvier MMol. Endocrinol. 2004-08-01 ;18( 8 ):2074-84
July 23, 2004 Structure of the C-terminal RING finger from a RING-IBR-RING/TRIAD motif reveals a novel zinc-binding domain distinct from a RING. Capili AD, Edghill EL, Wu K, Borden KJ. Mol. Biol. 2004-07-23 ;340( 5 ):1117-29
July 2, 2004 Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. Breit A, Lagacé M, Bouvier MJ. Biol. Chem. 2004-07-02 ;279( 27 ):28756-65
July 1, 2004 N-Terminal ubiquitination of extracellular signal-regulated kinase 3 and p21 directs their degradation by the proteasome. Coulombe P, Rodier G, Bonneil E, Thibault P, Meloche SMol. Cell. Biol. 2004-07-01 ;24( 14 ):6140-50
July 1, 2004 Pharmacological chaperones: potential treatment for conformational diseases. Bernier V, Lagacé M, Bichet DG, Bouvier MTrends Endocrinol. Metab. 2004-07-01 ;15( 5 ):222-8
July 1, 2004 Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. Thibeault D, Bousquet C, Gingras R, Lagacé L, Maurice R, White PW, Lamarre DJ. Virol. 2004-07-01 ;78( 14 ):7352-9